BR112018013881A8 - Vacina de neoepítopo anticâncer terapêutica - Google Patents
Vacina de neoepítopo anticâncer terapêuticaInfo
- Publication number
- BR112018013881A8 BR112018013881A8 BR112018013881A BR112018013881A BR112018013881A8 BR 112018013881 A8 BR112018013881 A8 BR 112018013881A8 BR 112018013881 A BR112018013881 A BR 112018013881A BR 112018013881 A BR112018013881 A BR 112018013881A BR 112018013881 A8 BR112018013881 A8 BR 112018013881A8
- Authority
- BR
- Brazil
- Prior art keywords
- vaccine
- cancer
- unit
- antigenic
- polynucleotide
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title abstract 5
- 230000001093 anti-cancer Effects 0.000 title abstract 2
- 230000001225 therapeutic effect Effects 0.000 title abstract 2
- 230000000890 antigenic effect Effects 0.000 abstract 4
- 239000002157 polynucleotide Substances 0.000 abstract 4
- 102000040430 polynucleotide Human genes 0.000 abstract 4
- 108091033319 polynucleotide Proteins 0.000 abstract 4
- 206010028980 Neoplasm Diseases 0.000 abstract 3
- 201000011510 cancer Diseases 0.000 abstract 3
- 229920001184 polypeptide Polymers 0.000 abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 3
- 239000011230 binding agent Substances 0.000 abstract 2
- 229940022399 cancer vaccine Drugs 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 238000006471 dimerization reaction Methods 0.000 abstract 1
- 239000002773 nucleotide Substances 0.000 abstract 1
- 125000003729 nucleotide group Chemical group 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 230000008685 targeting Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001116—Receptors for cytokines
- A61K39/001121—Receptors for chemokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6056—Antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
- A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/876—Skin, melanoma
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
?VACINA DE NEOEPÍTOPO ANTICÂNCER TERAPÊUTICA?, a presente invenção refere-se a uma vacina anticâncer que compreende polinucleotídeos ou polipeptídeos, métodos de tratamento de câncer em que tal vacina anticâncer é usada, assim como métodos para produzir a vacina. A vacina compreende um polinucleotídeo que compreende uma sequência de nucleotídeos de codificação de uma unidade de alvejamento, uma unidade de dimerização, um primeiro aglutinante e uma unidade antigênica, em que a dita unidade antigênica compreende subunidades antigênicas n-1, sendo que cada subunidade compreende pelo menos uma parte de uma sequência de neoepítopos de câncer e um segundo aglutinante e a dita unidade antigênica compreendem adicionalmente uma sequência de neoepítopos de câncer final, em que n é um número inteiro de 3 a 50, ou a vacina compreende um polipeptídeo codificado pelo polinucleotídeo ou uma proteína dimérica que consiste em dois polipeptídeos codificados pelo polinucleotídeo.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP16150574.8 | 2016-01-08 | ||
EP16150574 | 2016-01-08 | ||
EP16178393 | 2016-07-07 | ||
EP16178393.1 | 2016-07-07 | ||
PCT/EP2017/050206 WO2017118695A1 (en) | 2016-01-08 | 2017-01-05 | Therapeutic anticancer neoepitope vaccine |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112018013881A2 BR112018013881A2 (pt) | 2018-12-18 |
BR112018013881A8 true BR112018013881A8 (pt) | 2023-05-09 |
Family
ID=57821954
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112018013881A BR112018013881A8 (pt) | 2016-01-08 | 2017-01-05 | Vacina de neoepítopo anticâncer terapêutica |
Country Status (10)
Country | Link |
---|---|
US (2) | US20190022202A1 (pt) |
EP (1) | EP3400004A1 (pt) |
JP (2) | JP2019505512A (pt) |
KR (1) | KR20180100659A (pt) |
CN (1) | CN108495649A (pt) |
AU (1) | AU2017205270B2 (pt) |
BR (1) | BR112018013881A8 (pt) |
CA (1) | CA3008437A1 (pt) |
IL (1) | IL260030A (pt) |
WO (1) | WO2017118695A1 (pt) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2862878B1 (en) * | 2003-02-25 | 2022-11-02 | Nykode Therapeutics ASA | Modified antibody |
TW201930340A (zh) * | 2017-12-18 | 2019-08-01 | 美商尼恩醫療公司 | 新抗原及其用途 |
TWI787500B (zh) | 2018-04-23 | 2022-12-21 | 美商南特細胞公司 | 新抗原表位疫苗及免疫刺激組合物及方法 |
US11564980B2 (en) | 2018-04-23 | 2023-01-31 | Nantcell, Inc. | Tumor treatment method with an individualized peptide vaccine |
CN113631185A (zh) * | 2019-02-27 | 2021-11-09 | 尼克塔治疗公司 | 用于治疗癌症的免疫治疗组合 |
WO2020221783A1 (en) * | 2019-04-29 | 2020-11-05 | Vaccibody As | Methods for pre-selection of neoepitopes |
KR20220110181A (ko) * | 2019-10-09 | 2022-08-05 | 에드워드 프리츠 | 다중-도메인 단백질 백신 |
EP4132959A1 (en) * | 2020-04-07 | 2023-02-15 | Evaxion Biotech A/S | Neoepitope immunotherapy with apc targeting unit |
MX2022012671A (es) | 2020-04-09 | 2023-01-05 | Nykode Therapeutics ASA | Vacuna terapeutica individualizada contra el cancer. |
MX2022013661A (es) | 2020-05-01 | 2022-11-30 | Nykode Therapeutics ASA | Vacuna y uso de la misma en la profilaxis y terapia de betacoronavirus. |
BR112023019610A2 (pt) | 2021-03-26 | 2023-12-12 | Genentech Inc | Método para tratar um sujeito com câncer, e, kit |
EP4333881A1 (en) | 2021-05-03 | 2024-03-13 | Nykode Therapeutics ASA | Immunogenic constructs and vaccines for use in the prophylactic and therapeutic treatment of infectious diseases |
WO2022238395A1 (en) | 2021-05-10 | 2022-11-17 | Nykode Therapeutics ASA | Tolerance-inducing constructs and compositions and their use for the treatment of immune disorders |
WO2022238363A1 (en) | 2021-05-10 | 2022-11-17 | Nykode Therapeutics ASA | Immunogenic constructs and vaccines for use in the prophylactic and therapeutic treatment of infectious diseases |
KR20240019135A (ko) | 2021-05-10 | 2024-02-14 | 니코데 테라퓨틱스 에이에스에이 | 작제물과 면역자극 화합물의 공동발현 |
WO2022238381A2 (en) | 2021-05-10 | 2022-11-17 | Nykode Therapeutics ASA | Immunotherapy constructs for treatment of disease |
AU2022272650A1 (en) | 2021-05-10 | 2023-10-12 | Nykode Therapeutics ASA | Co-expression of constructs and immunoinhibitory compounds |
CA3218097A1 (en) | 2021-05-10 | 2022-11-17 | Agnete Brunsvik Fredriksen | Tolerance-inducing constructs and composition and their use for the treatment of immune disorders |
AU2022277246A1 (en) * | 2021-05-18 | 2024-01-04 | Hung, Mien-Chie | Vaccine, use thereof and cancer vaccine cocktail |
CA3235174A1 (en) | 2021-11-03 | 2023-05-11 | Peter Ebert | Immunogenic constructs and vaccines for use in the prophylactic and therapeutic treatment of diseases caused by sars-cov-2 |
WO2024092025A1 (en) | 2022-10-25 | 2024-05-02 | Nykode Therapeutics ASA | Constructs and their use |
WO2024100196A1 (en) | 2022-11-09 | 2024-05-16 | Nykode Therapeutics ASA | Co-expression of constructs and polypeptides |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2862878B1 (en) * | 2003-02-25 | 2022-11-02 | Nykode Therapeutics ASA | Modified antibody |
MX2007015933A (es) * | 2005-06-17 | 2008-04-21 | Mannkind Corp | Metodos y composiciones para generar respuestas inmunes multivalentes contra espitopes dominantes y subdominantes, expresados en celulas cancerigenas y estromas tumorales. |
DK2585107T3 (en) * | 2010-06-25 | 2019-02-11 | Vaccibody As | Homodimeric protein constructs |
RS62497B1 (sr) * | 2011-05-24 | 2021-11-30 | BioNTech SE | Individualizovane vakcine protiv kancera |
WO2012159643A1 (en) * | 2011-05-24 | 2012-11-29 | Biontech Ag | Individualized vaccines for cancer |
TW201302800A (zh) * | 2011-06-10 | 2013-01-16 | Oncotherapy Science Inc | Sema5b胜肽及含其之疫苗 |
-
2017
- 2017-01-05 EP EP17700495.9A patent/EP3400004A1/en active Pending
- 2017-01-05 US US16/068,449 patent/US20190022202A1/en not_active Abandoned
- 2017-01-05 AU AU2017205270A patent/AU2017205270B2/en active Active
- 2017-01-05 WO PCT/EP2017/050206 patent/WO2017118695A1/en active Application Filing
- 2017-01-05 CN CN201780006124.2A patent/CN108495649A/zh active Pending
- 2017-01-05 BR BR112018013881A patent/BR112018013881A8/pt unknown
- 2017-01-05 KR KR1020187022898A patent/KR20180100659A/ko active Search and Examination
- 2017-01-05 CA CA3008437A patent/CA3008437A1/en active Pending
- 2017-01-05 JP JP2018535138A patent/JP2019505512A/ja active Pending
-
2018
- 2018-06-14 IL IL260030A patent/IL260030A/en unknown
-
2021
- 2021-11-05 JP JP2021180825A patent/JP2022017499A/ja active Pending
- 2021-12-21 US US17/557,988 patent/US20220370579A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2019505512A (ja) | 2019-02-28 |
EP3400004A1 (en) | 2018-11-14 |
CN108495649A (zh) | 2018-09-04 |
US20220370579A1 (en) | 2022-11-24 |
JP2022017499A (ja) | 2022-01-25 |
AU2017205270B2 (en) | 2024-01-18 |
IL260030A (en) | 2018-07-31 |
AU2017205270A1 (en) | 2018-06-28 |
RU2018129062A (ru) | 2020-02-10 |
WO2017118695A1 (en) | 2017-07-13 |
CA3008437A1 (en) | 2017-07-13 |
US20190022202A1 (en) | 2019-01-24 |
KR20180100659A (ko) | 2018-09-11 |
BR112018013881A2 (pt) | 2018-12-18 |
RU2018129062A3 (pt) | 2020-04-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112018013881A8 (pt) | Vacina de neoepítopo anticâncer terapêutica | |
BR112022026733A2 (pt) | Imunógenos estabilizados de proteína spike (s) de coronavírus e vacinas relacionadas | |
CY1124896T1 (el) | Αντισωματα κατα της αλφα-συνουκλεïνης και χρησεις αυτων | |
BR112018072485A2 (pt) | proteínas de ligação biespecíficas e usos das mesmas | |
BR112018016281A2 (pt) | molécula biespecífica ativadora de célula t ativável por protease, polipeptídeo idiotipo-específico, composição farmacêutica, usos da molécula biespecífica e método de tratamento de uma doença em um indivíduo | |
SA518400424B1 (ar) | جزيئات الجسم المضاد لعلاج السرطان | |
BR112017023374A2 (pt) | formulação de anticorpo anti-cgrp | |
BR112016030462A2 (pt) | moléculas de ligação, um ou mais polinucleotídeos isolados, um ou mais vetores, célula hospedeira, método de produção de uma molécula de ligação, composição farmacêutica, uso da molécula de ligação, método de tratamento de doenças e de indução da lise de células alvo | |
CO2018004094A2 (es) | Polipéptidos de unión a cd3 | |
BR112016013493A2 (pt) | molécula de ácido nucleico, composição, vacina, e, métodos para prevenção de uma doença em um indivíduo com necessidade da mesma e para tratamento de uma doença em um indivíduo com necessidade do mesmo | |
MX2018001567A (es) | Novedosos polipeptidos de fusion especificos para lag-3 y pd-1. | |
BR112016023979A2 (pt) | métodos de melhora ou aceleração da recuperação física após cirurgia para fratura óssea | |
BR112018000835A2 (pt) | molécula, um ou mais polinucleotídeos, um ou mais vetores, célula, método de produção da molécula, composição, uso da molécula, método de tratamento de uma doença e método para induzir a lise de uma célula-alvo | |
BR112017007093A2 (pt) | composições e métodos de uso para aumento da resposta imune e terapia do câncer | |
EA201690868A1 (ru) | Персонализированная иммунотерапия нескольких видов нейрональных опухолей и опухолей головного мозга | |
CO2019002609A2 (es) | Proteínas de unión recombinantes y sus usos | |
MX2017014083A (es) | Polipeptido de fusion anti-cancer. | |
UY35682A (es) | Anticuerpos anti-activina a y usos de los mismos | |
UY36154A (es) | Anticuerpos contra el receptor del factor de necrosis tumoral inducido por glucocorticoides (gitr) y sus usos | |
CO2017009433A2 (es) | Proteínas específicas para pioverdina y pioquelina | |
CO2019003951A2 (es) | Proteínas de unión a cd123 y composiciones y métodos relacionados | |
EA201492230A1 (ru) | Новые схемы первично-повторной иммунизации, включающие иммуногенные полипептиды, кодируемые полинуклеотидами | |
BR112017011556A2 (pt) | métodos para gerar um anticorpo sintético, prevenir ou tratar uma doença, tratar um sujeito de infecção por um patógeno e um sujeito com câncer, produto, molécula de ácido nucleico, e, composição. | |
CR20160593A (es) | Anticuerpos antagonistas del interferon alfa y omega | |
CO2017005566A2 (es) | Péptidos cíclicos derivados de cd44v6 para el tratamiento de enfermedades relacionadas con cánceres y angiogénesis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
B25D | Requested change of name of applicant approved |
Owner name: NYKODE THERAPEUTICS AS (NO) |
|
B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
B25D | Requested change of name of applicant approved |
Owner name: NYKODE THERAPEUTICS ASA (NO) |